Genocea Provides Fourth Quarter 2021 Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Genocea Biosciences (GNCA) Tops Q4 EPS by 1c
March 10, 2022 7:01 AM ESTGenocea Biosciences (NASDAQ: GNCA) reported Q4 EPS of ($0.19), $0.01 better than the analyst estimate of ($0.20).
Genoceas existing cash is sufficient to support our current operations into Q3 2022, however we have strategic plans to extend our operations into 2023.
For earnings history and earnings-related data on Genocea Biosciences (GNCA) click here.
... More